NBOMes and DOx (25I-NBOMe, DOB, DOC, DOI)

psilodex.org/m/nbome-dox · data v2026.10.02

Clinical contraindication: Relative; Substantial clinical concern; the literature treats it as a reason for caution or deferral.
Best available evidence: Case reports; Also: mechanism only.
Half-life: Not recorded

Named in state rules?

CONot named

ORNot named

NMPending

Cite asPsilodex: nbome-dox · v2026.10.02

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

01 Interaction with psilocybin

CR · Th

Highly potent 5-HT2A agonists often sold on blotter as LSD. Reported toxicity includes seizures, tachycardia, hypertension, hyperthermia and, with DOB, diffuse vasospasm; deaths have occurred. Effects would add to psilocybin's at the same receptor.

Human data with psilocybin: Case reports or surveys only

Evidence types on this record

CRCase reports or online surveys

ThMechanism only (theoretical)

02 Pharmacology relevant to psilocybin

2 listed · counted on reports

Lowers seizure threshold or carries seizure risk: Makes a seizure more likely, or has been linked to seizures. Sources [1][3]
Raises blood pressure or heart rate: Raises blood pressure or heart rate. Psilocybin raises both for several hours, so the effects can add. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-02

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

Zawilska JB, Kacela M, Adamowicz P. NBOMes — highly potent and toxic alternatives of LSD. Front Neurosci 2020;14:78. — ultrapotent 5-HT2A agonists; blotters; seizures, tachycardia, hypertension, hyperthermia; fatalities
Bowen JS, Davis GB, Kearney TE, Bardin J. Diffuse vascular spasm associated with 4-bromo-2,5-dimethoxyamphetamine ingestion. JAMA 1983;249(11):1477–1479. PMID 6827726. — diffuse vascular spasm after DOB ingestion
Balíková M. Nonfatal and fatal DOB (2,5-dimethoxy-4-bromoamphetamine) overdose. Forensic Sci Int 2005;153(1):85–91. — DOB sold as 'LSD-like'; coma, convulsions, one death

Record history

v2026.10.02First published.
2026-10-02Last reviewed against its sources.

Report an error in this record →